Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?

Author： Paplomata Elisavet   Nahta Rita   O'Regan Ruth M.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|4|517-526

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.4, 2015-02, pp. : 517-526

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L.   Keam Susan J.  

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 449-475

Adis International

Access to resources Recommend Favorite

Serum Her-2/neu and Survivin Levels and Their Relationship to Histological Parameters in Early-stage Breast Cancer

By Goksel G   Taneli F   Uslu R   Ulman C   Dinc G   Coskun T   Kandiloglu AR  

The Journal of International Medical Research, Vol. 35, Iss. 2, 2007-03 ,pp. : 165-172

Field House Publishing

Access to resources Recommend Favorite

Adjuvant Hormonal Therapy in Women with Early-stage Breast Cancer

By  

Medicinal Chemistry, Vol. 12, Iss. 3, 2016-05 ,pp. : 261-267

Bentham Science Publishers

Access to resources Recommend Favorite

The Croatian government is to pay for early-stage human epidermal growth factor receptor 2-positive breast cancer patients to receive Roche's Herceptin

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 526, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe   Bettio Daniela   Torri Valter   Masci Giovanna   Salvini Piermario   Santoro Armando  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite